Blood Pressure Management in Metabolic Syndrome

被引:0
作者
Yano, Yuichiro [1 ]
Hoshide, Satoshi [1 ]
Shimada, Kazuyuki [1 ]
Kario, Kazuomi [1 ]
机构
[1] Jichi Med Univ, Sch Med, Div Cardiovasc Med, Shimotsuke, Tochigi 3290498, Japan
关键词
Metabolic syndrome; morning hypertension; masked hypertension; prehypertension; renin-angiotensin-aldosterone system;
D O I
10.2174/157340208785132581
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
To assess 24-hour BP levels in subjects with metabolic syndrome is essential, because hypertension, which is the most prevalent component in the syndrome, makes the major contribution to cardiovascular risk. Because BP levels in subjects with metabolic syndrome are prone to be elevated in an out-of-office setting (i.e., nocturnal hypertension, morning hypertension), measurement of home and/or ambulatory BP levels is a promising method for managing the syndrome. The best treatment approach for this complex condition is a multifactorial one, much emphasis has been placed on RAAS inhibition, which is one of the most important factors in the disease, although there has been no clear evidence that RAAS inhibitors are more effective than other drugs for treatment of metabolic syndrome. However, previous trials for treating hypertension have generally enrolled non-obese patients, and have enrolled more complicated high-risk patients, in whom the most important issue is BP lowering itself. here is thus a need to assess how to treat relatively younger subjects withmilder and/or high-normal hypertension, because the prevalence of such patients is expected to increase dramatically along with burgeoning obesity rates.
引用
收藏
页码:214 / 226
页数:13
相关论文
共 122 条
[11]   Predictors of all-cause mortality in clinical ambulatory monitoring - Unique aspects of blood pressure during sleep [J].
Ben-Dov, Iddo Z. ;
Kark, Jeremy D. ;
Ben-Ishay, Drori ;
Mekler, Judith ;
Ben-Arie, Liora ;
Bursztyn, Michael .
HYPERTENSION, 2007, 49 (06) :1235-1241
[12]   Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity [J].
Benson, SC ;
Pershadsingh, HA ;
Ho, CI ;
Chittiboyina, A ;
Desai, P ;
Pravenec, M ;
Qi, NN ;
Wang, JM ;
Avery, MA ;
Kurtz, TW .
HYPERTENSION, 2004, 43 (05) :993-1002
[13]   Plasma aldosterone is independently associated with the metabolic syndrome [J].
Bochud, Murielle ;
Nussberger, Jurg ;
Bovet, Pascal ;
Maillard, Marc R. ;
Elston, Robert C. ;
Paccaud, Fred ;
Shamlaye, Conrad ;
Burnier, Michel .
HYPERTENSION, 2006, 48 (02) :239-245
[14]  
Bosch J, 2006, NEW ENGL J MED, V355, P1551
[15]   Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets [J].
Brown, Jonathan D. ;
Plutzky, Jorge .
CIRCULATION, 2007, 115 (04) :518-533
[16]  
Calhoun David A, 2007, J Clin Hypertens (Greenwich), V9, P19, DOI 10.1111/j.1524-6175.2007.06334.x
[17]  
Chamontin, 1996, Blood Press Monit, V1, P329
[18]   Different association of hypertension and insulin-related metabolic syndrome between men and women in 8437 nondiabetic Chinese [J].
Chen, CH ;
Lin, KC ;
Tsai, ST ;
Chou, P .
AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (07) :846-853
[19]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[20]   Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome [J].
Coughlin, SR ;
Mawdsley, L ;
Mugarza, JA ;
Calverley, PMA ;
Wilding, JPH .
EUROPEAN HEART JOURNAL, 2004, 25 (09) :735-741